Olga Mollin

Olga Mollin has a comprehensive work experience in the pharmaceutical and biotechnology industry. Olga started their career at Lonza in 1999, where they held various roles in manufacturing and quality assurance. Olga managed commercial cell culture suites, conducted process technology transfers, and served as an expert in contamination investigation.

In 2006, Olga became the Head of Manufacturing at Lonza, overseeing two production lines and the Manufacturing team. Olga also served as the Virtual Plant Manager at Bioverativ, a Sanofi company, responsible for ensuring CMO performance and managing contract and program management.

Olga joined Sanofi in 2018 as the Senior Director of Specialty Care External Supply, where they were accountable for global product supply, readiness for product launch, and regulatory market management. Olga also worked with multiple CMOs through various contracts.

In their most recent role at Affinivax Inc., Olga served as the VP of Global Manufacturing and Supply. Olga was responsible for end-to-end manufacturing and supply for the AFX3772 MAPS™ vaccine program and subsequent vaccine pipeline. The company was acquired by GSK in 2022, and Olga's role was integrated into the GSK global organization.

Currently, Olga is the VP and Watertown Site Head of Technical Operations at Landmark Bio, starting in 2023.

Olga Mollin holds a Bachelor's Degree in Biotechnology from Dublin City University. Additionally, they have pursued further education and obtained a Master of Business Administration (M.B.A.) from the UNH Peter T. Paul College of Business and Economics. The chronological information provided does not specify the start and end years for either of these educational pursuits.